Ryan Brudner
Research affiliate in psychiatry at the University of Toronto / affiliated with the Mood Disorder Psychopharmacology Unit and related psilocybin research teams
Data updated
Papers
Trials
Research Footprint
Ryan Brudner appears in 5 tracked papers (2024–2025), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Bipolar Disorder.
Most-cited paper: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin (89 citations).
Frequent co-authors: Zoe Doyle, Roger McIntyre and Jonathan Rosenblat.
Background & Research
Ryan M Brudner appears to be a researcher based in Toronto involved in psychiatry and psychedelic clinical research. He is listed as a coauthor on several psilocybin-assisted psychotherapy papers from the University of Toronto/UHN-associated research network, including studies on treatment-resistant depression, mystical experience, bipolar II disorder, and cognitive outcomes.
Key Impact
He is a coauthor on multiple clinical studies of psilocybin-assisted psychotherapy for treatment-resistant depression, including randomized trial analyses and related outcome papers.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Ryan Brudner's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Ryan Brudner is associated with.
Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →